Gérald Voss

6.5k citations

75 papers · 4.3k indexed · 1 hit paper · h-index 31

Impact in

Virology top 0.2%
- HIV Research and Treatment
Immunology top 1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology

Papers in ⓘ

Virology 50
- HIV Research and Treatment 49
Immunology 37
- Immune Cell Function and Interaction 27
- T-cell and B-cell Immunology 10
- Immunotherapy and Immune Responses 10

Co-authors: Kent E. Kester (11 shared papers)John R. Mascola (5 shared papers)Norman L. Letvin (9 shared papers)David C. Montefiori (5 shared papers)Joe Cohen (11 shared papers)Marguerite Koutsoukos (12 shared papers)Nadia Tornieporth (7 shared papers)Paul A. Goepfert (2 shared papers)
Journals: Vaccine (14 papers)Journal of Virology (9 papers)Journal of General Virology (5 papers)Virology (5 papers)AIDS Research and Human Retroviruses (4 papers)
Partner nations: United States Belgium United Kingdom

In The Last Decade

Gérald Voss

73 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies 2005 · 845 citations

Peers

Countries citing papers authored by Gérald Voss

Since Specialization

Citations

This map shows the geographic impact of Gérald Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gérald Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gérald Voss more than expected).

Fields of papers citing papers by Gérald Voss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gérald Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gérald Voss. The network helps show where Gérald Voss may publish in the future.

Co-authors

The 25 scholars most cited alongside Gérald Voss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gérald Voss Line = papers co-authored together Gérald Voss links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies Journal of Virology ·Ming Li, Feng Gao, John R. Mascola, Leonidas Stamatatos, Victoria R. Polonis, Marguerite Koutsoukos, Gérald Voss, Paul A. Goepfert, Peter B. Gilbert, Kelli Greene, Miroslawa Bilska, Denise L. Kothe, Jesus F. Salazar-Gonzalez, Xiping Wei, Julie M. Decker, Beatrice H. Hahn, David C. Montefiori Hit paper breakdown →	2005	845
2	Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial The Lancet ·Kalifa Bojang, Paul Milligan, Margaret Pinder, Laurence Vigneron, Ali Alloueche, Kent E. Kester, W. Ripley Ballou, David J. Conway, William H. H. Reece, Philip Gothard, Lawrence Yamuah, Martine Delchambre, Gérald Voss, Brian Greenwood, Adrian V. S. Hill, Keith P. W. J. McAdam, Nadia Tornieporth, Joe Cohen, Tom Doherty	2001	395
3	A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease Nature Medicine ·William H. H. Reece, Margaret Pinder, Philip Gothard, Paul Milligan, Kalifa Bojang, Tom Doherty, Magdalena Plebanski, Peter Akinwunmi, S. Everaere, Katherine R. Watkins, Gérald Voss, Nadia Tornieporth, Ali Alloueche, Brian Greenwood, Kent E. Kester, Keith P. W. J. McAdam, Joe Cohen, Adrian V. S. Hill	2004	217
4	An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys Journal of Virology ·Keith A. Reimann, J T Li, Gérald Voss, Christine Lekutis, Klara Tenner‐Racz, Paul Rácz, Wenyu Lin, David C. Montefiori, David Lee‐Parritz, Yue Lu, Ronald G. Collman, Joseph Sodroski, Norman L. Letvin	1996	200
5	Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria The Journal of Infectious Diseases ·Kent E. Kester, Denise McKinney, Nadia Tornieporth, Christian F. Ockenhouse, D. Gray Heppner, Ted Hall, Urszula Krzych, Martine Delchambre, Gérald Voss, Megan Dowler, Jolie Palensky, Janet Wittes, Joe Cohen, W. Ripley Ballou, (unknown)	2001	199
6	Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ The Journal of Immunology ·Peifang Sun, Robert Schwenk, Katherine White, José A. Stoute, Joe Cohen, W. Ripley Ballou, Gérald Voss, Kent E. Kester, D. Gray Heppner, Urszula Krzych	2003	183
7	Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants Journal of Virology ·Y. Li, Krisha Svehla, Nathalie Mathy, Gérald Voss, John R. Mascola, Richard T. Wyatt	2006	142
8	Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine The Journal of Infectious Diseases ·Ajit Lalvani, Phillipe Moris, Gérald Voss, Ansar A. Pathan, Kent E. Kester, Roger H. Brookes, Edwin Lee, Marguerite Koutsoukos, Magdalena Plebanski, Martine Delchambre, Katie L. Flanagan, Cecile Carton, M. Slaoui, Christian Van Hoecke, W. Ripley Ballou, Adrian V. S. Hill, Joe Cohen	1999	131
9	An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model Vaccine ·J. Robert Putnak, Beth-Ann Coller, Gérald Voss, David W. Vaughn, David E. Clements, Iain D. Peters, Gary S. Bignami, Hou-Shu Houng, Robert C.-M. Chen, David A. Barvir, J Seriwatana, Sylvie Cayphas, Nathalie Garçon, Dirk Gheysen, Niranjan Kanesa-thasan, Mike McDonell, Tom Humphreys, Kenneth H. Eckels, Jean‐Paul Prieels, Bruce L. Innis	2005	130
10	Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile Immunology Letters ·Nancy L. Haigwood, Andrew J. Watson, William F. Sutton, Jan McClure, Anne D. Lewis, Jane Ranchalis, Bruce Travis, Gérald Voss, Norman L. Letvin, Shiu-Lok Hu, Vanessa M. Hirsch, Philip R. Johnson	1996	114
11	Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys Journal of Virology ·Yasuhiro Yasutomi, Harriet L. Robinson, Shuai Lü, Farah Mustafa, Christine Lekutis, James Arthos, James I. Mullins, Gérald Voss, Kelledy Manson, Michael S. Wyand, Norman L. Letvin	1996	113
12	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site PLoS Pathogens ·Barna Dey, Krisha Svehla, Ling Xu, Dianne Wycuff, Tongqing Zhou, Gérald Voss, Adhuna Phogat, Bimal K. Chakrabarti, Yuxing Li, George Shaw, Peter D. Kwong, Gary J. Nabel, John R. Mascola, Richard T. Wyatt	2009	98
13	Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies Journal of Virology ·Nancy L. Haigwood, David C. Montefiori, William F. Sutton, Janela McClure, Andrew J. Watson, Gérald Voss, Vanessa M. Hirsch, Barbra A. Richardson, Norman L. Letvin, Shiu-Lok Hu, Philip R. Johnson	2004	81
14	Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A Vaccine ·V. Ann Stewart, Shannon McGrath, Douglas S. Walsh, Stacey Davis, Aaron S. Hess, Lisa A. Ware, Kent E. Kester, James F. Cummings, J. Robert Burge, Gérald Voss, Martine Delchambre, Nathalie Garçon, Douglas B. Tang, Joe Cohen, D. Gray Heppner	2006	74
15	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers Vaccine ·Paul A. Goepfert, Georgia D. Tomaras, Helen Horton, David C. Montefiori, Guido Ferrari, Mark Deers, Gérald Voss, Marguerite Koutsoukos, Louise Pedneault, Pierre Vandepapelière, M. Juliana McElrath, Paul Spearman, Jonathan D. Fuchs, Beryl A. Koblin, William A. Blattner, Sharon E. Frey, Lindsey R. Baden, Clayton Harro, Thomas G. Evans	2006	71
16	A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. American Journal of Tropical Medicine and Hygiene ·J.F. Doherty, M Pinder, Nadia Tornieporth, C Carton, Laurence Vigneron, Paul Milligan, W. Ripley Ballou, Carolyn A. Holland, Kent E. Kester, Gérald Voss, P. Momin, Brian Greenwood, Keith P. W. J. McAdam, Joe Cohen	1999	66
17	Use of Major Histocompatibility Complex Class I/Peptide/β2M Tetramers To Quantitate CD8⁺Cytotoxic T Lymphocytes Specific for Dominant and Nondominant Viral Epitopes in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys Journal of Virology ·Michael A. Egan, Marcelo J. Kuroda, Gérald Voss, Jörn E. Schmitz, William A. Charini, Carol I. Lord, Meryl A. Forman, Norman L. Letvin	1999	61
18	Simian Immunodeficiency Virus Evades a Dominant Epitope-Specific Cytotoxic T Lymphocyte Response Through a Mutation Resulting in the Accelerated Dissociation of Viral Peptide and MHC Class I The Journal of Immunology ·Zheng W. Chen, Abie Craiu, Ling Shen, Marcelo J. Kuroda, Ugonna C. Iroku, David I. Watkins, Gérald Voss, Norman L. Letvin	2000	60
19	Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization Proceedings of the National Academy of Sciences ·Pengfei Zhang, Fatim Cham, Ming Dong, Anil Choudhary, Peter Bouma, Zhiqiang Zhang, Yiming Shao, Yanru Feng, Lemin Wang, Nathalie Mathy, Gérald Voss, Christopher C. Broder, Gerald V. Quinnan	2007	60
20	B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4 PLoS Pathogens ·Mattias N.E. Forsell, Barna Dey, Andreas Mörner, Krisha Svehla, Sijy O’Dell, Carl‐Magnus Högerkorp, Gérald Voss, Rigmor Thorstensson, George M. Shaw, John R. Mascola, Gunilla B. Karlsson Hedestam, Richard T. Wyatt	2008	57

About Gérald Voss

Gérald Voss is a scholar working on Virology, Immunology, Infectious Diseases, Epidemiology and Molecular Biology, having authored 75 papers that have together received 4.3k indexed citations. Recurring topics across this work include HIV Research and Treatment (49 papers), Immune Cell Function and Interaction (27 papers), vaccines and immunoinformatics approaches (13 papers), T-cell and B-cell Immunology (10 papers), Malaria Research and Control (10 papers), Immunotherapy and Immune Responses (10 papers), Herpesvirus Infections and Treatments (10 papers) and HIV/AIDS Research and Interventions (9 papers). The work is most often cited by research in Virology (2.5k citations), Immunology (2.1k citations), Infectious Diseases (1.2k citations), Public Health, Environmental and Occupational Health (1.2k citations) and Epidemiology (1.0k citations). Gérald Voss has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Kent E. Kester, John R. Mascola, Norman L. Letvin, David C. Montefiori, Joe Cohen, Marguerite Koutsoukos, Nadia Tornieporth, Paul A. Goepfert, Martine Delchambre and Leonidas Stamatatos. Their work appears in journals such as Vaccine, Journal of Virology, Journal of General Virology, Virology and AIDS Research and Human Retroviruses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact